コンテンツへスキップ
Merck
すべての画像(3)

資料

安全性情報

SAB4300061

Sigma-Aldrich

Anti-phospho-ERBB2 (pTyr1248) antibody produced in rabbit

affinity isolated antibody

別名:

Anti-CD340 antibody produced in rabbit, Anti-HER-2 antibody produced in rabbit, Anti-HER-2/neu antibody produced in rabbit, Anti-HER2 antibody produced in rabbit, Anti-v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro / glioblastoma derived oncogene homolog (avian) antibody produced in rabbit

ログイン組織・契約価格を表示する
すべての画像(3)

About This Item

MDL番号:
MFCD06798486
UNSPSCコード:
12352203
NACRES:
NA.41

由来生物

rabbit

結合体

unconjugated

抗体製品の状態

affinity isolated antibody

抗体製品タイプ

primary antibodies

クローン

polyclonal

形状

buffered aqueous solution

分子量

~185 kDa

化学種の反応性

rat, mouse, human

濃度

1 mg/mL

テクニック

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:100
indirect immunofluorescence: 1:100-1:200
western blot: 1:500-1:1000

アイソタイプ

IgG

免疫原配列

(P-E-YP-L-G)

NCBIアクセッション番号

NP_001005862.1

UniProtアクセッション番号

P04626

輸送温度

wet ice

保管温度

−20°C

ターゲットの翻訳後修飾

phosphorylation (pTyr1248)

遺伝子情報

human ... ERBB2(2064)

関連するカテゴリー

免疫原

Peptide sequence around phosphorylation site of tyrosine1248 (P-E-Y(p)-L-G), according to the protein ERBB2.

特徴および利点

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

ターゲットの説明

Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Not activated by EGF, TGF-alpha and amphiregulin.

物理的形状

PBS（0.02％ アジ化ナトリウム、50％ グリセロール含有）

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our 製品選択ツール.

保管分類コード

10 - Combustible liquids

WGK

WGK 1

引火点(°F)

Not applicable

引火点(℃)

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

SAB4300061-100UG:

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Jianjie Zhu et al.
Journal of experimental & clinical cancer research : CR, 40(1), 192-192 (2021-06-11)
Tetraspanins CD151, a transmembrane 4 superfamily protein, has been identified participating in the initiation of a variety of cancers. However, the precise function of CD151 in non-small cell lung cancer (NSCLC) remains unclear. Here, we addressed the pro-tumoral role of
Jieqi Zhou et al.
Cell death & disease, 13(5), 486-486 (2022-05-22)
Disintegrin-metalloproteinase 15(ADAM15), a member of disintegrin metalloproteinases (ADAMs), plays important roles in various cancer types. However, the underlying ADAM15 functioning in lung cancer is still unclear. In the present study, we find that ADAM15 regulates the epidermal growth factor receptor/focal
Peter J Wild et al.
EMBO molecular medicine, 4(8), 808-824 (2012-06-09)
Type II endometrial carcinomas are a highly aggressive group of tumour subtypes that are frequently associated with inactivation of the TP53 tumour suppressor gene. We show that mice with endometrium-specific deletion of Trp53 initially exhibited histological changes that are identical
Toshio Shimizu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(19), 5032-5040 (2014-08-12)
This first-in-human phase I study evaluated dose-limiting toxicities (DLT) and defined a phase II recommended dose (RD) for CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 as a 1-hour intravenous (i.v.) infusion for 5 consecutive days every 2 weeks.
Yong Sang Hong et al.
PloS one, 9(10), e109440-e109440 (2014-10-29)
ERBB2-directed therapy is now a routine component of therapy for ERBB2-amplified metastatic gastroesophageal adenocarcinomas. However, there is little knowledge of the mechanisms by which these tumors develop acquired resistance to ERBB2 inhibition. To investigate this question we sought to characterize

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）